Eagle Pharmaceuticals Inc. logo

Eagle Pharmaceuticals Inc. Share Price Today (NASDAQ: EGRX)

Eagle Pharmaceuticals Inc. share price is $0 & ₹0.00 as on 2 Oct 2024 IST

-1.99

(-100%)

Live

Bell Icon

The stock has been delisted from the stock exchange on 3 Oct 2024

View live Eagle Pharmaceuticals Inc. share price in Dollar and Rupees. Guide to invest in Eagle Pharmaceuticals Inc. stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Eagle Pharmaceuticals Inc., along with analyst recommendations, forecasts, and comprehensive financials.

Eagle Pharmaceuticals Inc. (EGRX) Key Statistics

in dollars & INR

Previous Close
$1.99
Open
$1.9
Market Capitalization
$50.5M
Today's Volume
$1.5M
Revenue TTM
$257.6M
EBITDA
$62.3M
Earnings Per Share (EPS)
$0.85
PE Ratio
4.58
Profit Margin
4.64%
Quarterly Earnings Growth YOY
-0.87%
Return On Equity TTM
4.88%

How to invest in Eagle Pharmaceuticals Inc. Stock (EGRX) from India?

It is very easy for Indian residents to invest directly in Eagle Pharmaceuticals Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Eagle Pharmaceuticals Inc. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Eagle Pharmaceuticals Inc. or EGRX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Eagle Pharmaceuticals Inc. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Eagle Pharmaceuticals Inc. shares which would translate to null fractional shares of Eagle Pharmaceuticals Inc. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Eagle Pharmaceuticals Inc., in just a few clicks!

Global Institutional Holdings in Eagle Pharmaceuticals Inc.

  • Nantahala Capital Management, LLC

    30.28%

  • AIGH Capital Management, LLC

    9.35%

  • Citigroup Inc

    7.73%

  • AQR Capital Management LLC

    5.38%

  • Vanguard Group Inc

    4.36%

  • BlackRock Inc

    2.72%

Analyst Recommendation on Eagle Pharmaceuticals Inc.

Rating
Trend

Buy

    85%Buy

    14%Hold

    0%Sell

Based on 7 Wall street analysts offering stock ratings for Eagle Pharmaceuticals Inc.(by analysts ranked 0 to 5 stars)

About Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Organization
Eagle Pharmaceuticals Inc.
Employees
134
CEO
Mr. Michael Graves
Industry
Health Technology

Important FAQs about investing in EGRX Stock from India :

Can Indians buy Eagle Pharmaceuticals Inc. shares?

Yes, Indians can invest in the Eagle Pharmaceuticals Inc. (EGRX) from India.

With INDmoney, you can buy Eagle Pharmaceuticals Inc. at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Eagle Pharmaceuticals Inc. at zero transaction cost.

How can I buy Eagle Pharmaceuticals Inc. shares from India?

It is very easy to buy Eagle Pharmaceuticals Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Eagle Pharmaceuticals Inc. (EGRX) be purchased?

Yes, you can buy fractional shares of Eagle Pharmaceuticals Inc. with INDmoney app.

What are the documents required to start investing in Eagle Pharmaceuticals Inc. stocks?

To start investing in Eagle Pharmaceuticals Inc., You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Eagle Pharmaceuticals Inc.?

Today's market capitalisation of Eagle Pharmaceuticals Inc. EGRX is 50.5M

Who is the Chief Executive Officer (CEO) of Eagle Pharmaceuticals Inc. ?

Mr. Michael Graves is the current Chief Executive Officer (CEO) of Eagle Pharmaceuticals Inc..